269 related articles for article (PubMed ID: 30663770)
1. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats.
Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X
J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770
[TBL] [Abstract][Full Text] [Related]
2. Dextran sulfate sodium-induced colitis and ginseng intervention altered oral pharmacokinetics of cyclosporine A in rats.
Yang Y; Hu N; Gao XJ; Li T; Yan ZX; Wang PP; Wei B; Li S; Zhang ZJ; Li SL; Yan R
J Ethnopharmacol; 2021 Jan; 265():113251. PubMed ID: 32810615
[TBL] [Abstract][Full Text] [Related]
3. Baicalin pharmacokinetic profile of absorption process using novel in-vitro model: cytochrome P450 3A4-induced Caco-2 cell monolayers combined with rat intestinal rinse fluids.
Morisaki T; Hou XL; Takahashi K; Takahashi K
J Pharm Pharmacol; 2013 Oct; 65(10):1526-35. PubMed ID: 24028620
[TBL] [Abstract][Full Text] [Related]
4. Effects of sinapic acid on hepatic cytochrome P450 3A2, 2C11, and intestinal P-glycoprotein on the pharmacokinetics of oral carbamazepine in rats: Potential food/herb-drug interaction.
Raish M; Ahmad A; Ansari MA; Alkharfy KM; Ahad A; Al-Jenoobi FI; Al-Mohizea AM; Khan A; Ali N
Epilepsy Res; 2019 Jul; 153():14-18. PubMed ID: 30927680
[TBL] [Abstract][Full Text] [Related]
5. Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats.
Konishi H; Sumi M; Shibata N; Takada K; Minouchi T; Yamaji A
J Pharm Pharmacol; 2004 Oct; 56(10):1259-66. PubMed ID: 15482640
[TBL] [Abstract][Full Text] [Related]
6. An antioxidant Trolox restores decreased oral absorption of cyclosporine A after liver ischemia-reperfusion through distinct mechanisms between CYP3A and P-glycoprotein in the small intestine.
Ikemura K; Inoue K; Mizutani H; Oka H; Iwamoto T; Okuda M
Eur J Pharmacol; 2012 Sep; 690(1-3):192-201. PubMed ID: 22749977
[TBL] [Abstract][Full Text] [Related]
7. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
Choi SJ; Shin SC; Choi JS
Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
[TBL] [Abstract][Full Text] [Related]
8. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
[TBL] [Abstract][Full Text] [Related]
9. Effects of cyclosporine A and itraconazole on permeability, biliary excretion and pharmacokinetics of amlodipine.
Ni L; Yu X; Yu Q; Chen X; Jia L
Drug Metab Lett; 2008 Aug; 2(3):163-8. PubMed ID: 19356088
[TBL] [Abstract][Full Text] [Related]
10. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
Sharma P; Varma MV; Chawla HP; Panchagnula R
Farmaco; 2005; 60(11-12):874-83. PubMed ID: 16243320
[TBL] [Abstract][Full Text] [Related]
11. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
Choi JS; Choi I; Choi DH
Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
Suzuki K; Taniyama K; Aoyama T; Watanabe Y
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
[TBL] [Abstract][Full Text] [Related]
13. Effects of roxithromycin on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats.
Li C; Kim CS; Yang JY; Park YJ; Choi JS
Eur J Drug Metab Pharmacokinet; 2008; 33(4):231-6. PubMed ID: 19230596
[TBL] [Abstract][Full Text] [Related]
14. Impact of quercetin‑induced changes in drug‑metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats.
Liu Y; Luo X; Yang C; Yang T; Zhou J; Shi S
Mol Med Rep; 2016 Oct; 14(4):3073-85. PubMed ID: 27510982
[TBL] [Abstract][Full Text] [Related]
15. High-dose etoposide formulations do not saturate intestinal P-glycoprotein: Development, stability, and pharmacokinetics in Sprague-Dawley rats.
Al-Ali AAA; Sandra L; Versweyveld D; Pijpers I; Dillen L; Vermeulen A; Snoeys J; Holm R; Nielsen CU
Int J Pharm; 2020 Jun; 583():119399. PubMed ID: 32376439
[TBL] [Abstract][Full Text] [Related]
16. Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption.
Wei J; Liu R; Zhang J; Liu S; Yan D; Wen X; Tian X
Front Pharmacol; 2021; 12():761763. PubMed ID: 34819863
[No Abstract] [Full Text] [Related]
17. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats.
Hsiu SL; Hou YC; Wang YH; Tsao CW; Su SF; Chao PD
Life Sci; 2002 Dec; 72(3):227-35. PubMed ID: 12427482
[TBL] [Abstract][Full Text] [Related]
18. Possible roles of intestinal P-glycoprotein and cytochrome P450 3A on the limited oral absorption of irinotecan.
Yamasaki K; Hidaka M; Kawano Y; Furuya Y; Ono H; Arimori K
J Pharm Pharmacol; 2021 Mar; 73(2):178-184. PubMed ID: 33793796
[TBL] [Abstract][Full Text] [Related]
19. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.
Kageyama M; Namiki H; Fukushima H; Ito Y; Shibata N; Takada K
Biol Pharm Bull; 2005 Feb; 28(2):316-22. PubMed ID: 15684491
[TBL] [Abstract][Full Text] [Related]
20. Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone.
Yokogawa K; Shimada T; Higashi Y; Itoh Y; Masue T; Ishizaki J; Asahi M; Miyamoto K
Biochem Pharmacol; 2002 Feb; 63(4):777-83. PubMed ID: 11992648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
